Pfizer Ventures and Merck GHI both contributed to the cancer care technology provider's series B round, taking its overall funding to at least $38m.
Strata Oncology, a US-based developer of precision cancer care technology, has completed a $26m that included subsidiaries of pharmaceutical firms Pfizer and Merck & Co.
Pfizer Ventures and Merck Global Health Innovation Fund (Merck GHI) invested alongside Deerfield Management, Renaissance Venture Capital Fund, Arboretum Ventures and Baird Capital.
Strata has created a platform that helps healthcare providers put together a singular precision oncology treatment program that incorporates molecular profiling and precision therapy, and which can be provided cost-effectively at scale.
…
